Treatment of Bullous Dermatoses with Ciclosporin (CyA)

  • B.-R. Balda
  • D. Rosenzweig


Today pemphigus vulgaris, including its clinical variants pemphigus foliaceus, pemphigus erythematosus Senear-Usher etc., is generally accepted to be an autoimmune disease with intraepithelial IgG antibodies. For that reason treatment aims at achieving the most effective immunosuppression possible by the systemic administration of steroids and azathioprine and occasionally also methotrexate [7]. If the course of the disease is particularly severe and serum antibody levels are high, plasmapheresis is tried as an additional means of treatment [7, 8]. However, this form of therapy involves considerable side effects because the immunosuppression is not selective. Almost all proliferative cell systems are more or less equally affected by the cytotoxic effects of the above-mentioned drugs, and in particular the immunocompetent cells and the haemopoietic system. A number of authors also report an increased incidence of malignant tumours in patients who receive such immunosuppressive treatment over a prolonged period [6]. In addition there are always patients whose bullous condition cannot be arrested or healed despite the prolonged use of immunosuppressives in high doses.


Truncal Obesity Moon Face Bullous Eruption Bullous Dermatosis Gingival Hypertrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beveridge T (1982) Treatment of auto-immune conditions with Cyclosporin A. In: White DG (ed) Cyclosporin A. Elsevier Biomed Press, Amsterdam New York Oxford, pp 561–564Google Scholar
  2. 2.
    Beveridge T (1983) Cyclosporin A: An Evaluation of Clinical Results. Transplant Proc XV: 433–437Google Scholar
  3. 3.
    Beveridge T, Krupp P, McKibbin C (1984) Lymphomas and lymphoproliferative lesions developing under Cyclosporin therapy. Lancet 8380/I:788Google Scholar
  4. 4.
    Borel JF, Lafferty KJ (1983) Cyclosporine: Speculation about its mechanism of action. Transplant Proc 15:1881–1885Google Scholar
  5. 5.
    Borel JF, Stähelin H (1983) Cyclosporin A — Geschichte und Bedeutung seiner Entdeckung. Sandorama 2: 4–8Google Scholar
  6. 6.
    Kinlen LJ, Sheil AGR, Peto I, et al. (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J ii:1461–1466CrossRefGoogle Scholar
  7. 7.
    Lever WF, Schaumburg-Lever G (1984) Treatment of pemphigus vulgaris. Arch Dermatol 120:44–47PubMedCrossRefGoogle Scholar
  8. 8.
    Ruocco V, Astarita C, Pisani M (1984) Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica 168:219–223PubMedCrossRefGoogle Scholar

Copyright information

© Sandoz Ltd, Basle 1985

Authors and Affiliations

  • B.-R. Balda
  • D. Rosenzweig
    • 1
  1. 1.Dept. of Dermatology and Allergology, Augsburg, W. GermanyAugsburgW. Germany

Personalised recommendations